|Articles|March 3, 2020

Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer

https://www.pharmacytimes.org/on-demand/managed-care-considerations-for-navigating-biosimilar-and-her2-directed-therapies-for-the-treatment-of-her2-positive-breast-cancer

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Ultimately, the authors said most patients will have more than one viable treatment option for first-line therapy, meaning that clinicians will need to rely on careful, informed discussions with patients. | Image credit: Eleni - stock.adobe.com

Novel CLL Therapies Prompt New Treatment Considerations

ByJared Kaltwasser

January 24th 2026

Researchers identified 3 overarching themes: a prolonged journey with symptoms, multiple trials of therapy with inadequate control, and diverse experiences with AIT. | Image credit: Volha Zaitsava - stock.adobe.com

Highlighting Gaps in Allergic Rhinitis Care, Allergen Immunotherapy Access

ByRose McNulty

January 23rd 2026

The findings reinforce the need for earlier recognition of scarring alopecias—particularly CCCA—and improved education for clinicians. | Image Credit: cattyphoto - stock.adobe.com

CCCA Associated With Longer Time to Diagnosis Vs Other Scarring Alopecias

ByRose McNulty

January 23rd 2026

Health Equity & Access Weekly Roundup: January 23, 2026

ByGiuliana Grossi

January 23rd 2026

First-line anlotinib plus chemotherapy demonstrates favorable efficacy and manageable toxicity in advanced STS. | Image credit: @Aidman-Adobestock.jpeg

Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma

BySabrina McCrear

January 23rd 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer

Newsletter

Related Content

Novel CLL Therapies Prompt New Treatment Considerations

Highlighting Gaps in Allergic Rhinitis Care, Allergen Immunotherapy Access

CCCA Associated With Longer Time to Diagnosis Vs Other Scarring Alopecias

Health Equity & Access Weekly Roundup: January 23, 2026

Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

Novel CLL Therapies Prompt New Treatment Considerations

Congress Unveils Massive Funding Bill to Avert Shutdown

Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma

Highlighting Gaps in Allergic Rhinitis Care, Allergen Immunotherapy Access

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD